Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation

Feng Jing, Qian Zou, Yangyang Wang, Zhiyou Cai, and Yong Tang

Abstract

Background: Central sensitization is considered a critical pathogenic mechanism of chronic migraine (CM). Activation of microglia in the trigeminal nucleus caudalis (TNC) contributes to this progression. Microglial glucagon-like peptide-1 receptor (GLP-1R) activation can alleviate pain; however, whether it is involved in the mechanism of CM has not been determined. Thus, this study aims to investigate the precise role of GLP-1R in the central sensitization of CM.

Methods: Repeated nitroglycerin injection-treated mice were used as a CM animal model in the experiment. To identify the distribution and cell localization of GLP-1R in the TNC, we performed immunofluorescence staining. Changes in the expression of GLP-1R, Iba-1, PI3K, and p-Akt in the TNC were examined by western blotting. To confirm the effect of GLP-1R and PI3K/Akt in CM, a GLP-1R selective agonist (liraglutide) and antagonist (exendin(9–39)) and a PI3K selective antagonist (LY294002) were administered. Mechanical hypersensitivity was measured through von Frey filaments. To investigate the role of GLP-1R in central sensitization, calcitonin gene-related peptide (CGRP) and c-fos were determined using western blotting and immunofluorescence. To investigate the role of GLP-1R in central sensitization, calcitonin gene-related peptide (CGRP) and c-fos were determined using western blotting and immunofluorescence. To determine the changes in microglial activation, IL-1β and TNF-α were examined by western blotting, and the number and morphology of microglia were measured by immunofluorescence. We also confirmed the effect of GLP-1R on microglial activation in lipopolysaccharide-treated BV-2 microglia.

Results: The protein expression of GLP-1R was increased in the TNC after nitroglycerin injection. GLP-1R was colocalized with microglia and astrocytes in the TNC and was fully expressed in BV-2 microglia. The GLP-1R agonist liraglutide alleviated basal allodynia and suppressed the upregulation of CGRP, c-fos and P3K/p-Akt in the TNC. Similarly, the PI3K inhibitor LY294002 prevented nitroglycerin-induced hyperalgesia. In addition, activating GLP-1R reduced Iba-1, IL-1β and TNF-α release and inhibited TNC microglial number and morphological changes (process retraction) following nitroglycerin administration. In vitro, the protein levels of IL-1β and TNF-α in lipopolysaccharide-stimulated BV-2 microglia were also decreased by liraglutide.
Background

Chronic migraine (CM) is a severe neurological disease that seriously affects the daily life of patients and imposes a large economic burden on society [1, 2]. CM is the most common chronic headache in headache clinics in China [3]. The chronic condition of CM is attributable to repeated migraine attacks, and 2.5% of episodic migraine converts into CM each year [4, 5]. Therefore, early prophylactic treatment is necessary for improving the prognosis of CM patients. However, the present treatments for CM are not satisfactory [6], and the pathogenesis of CM is still not fully understood.

Accumulating evidence indicates that central sensitization is a critical mechanism of CM, which manifests as neuronal plastic changes in the trigeminal nucleus caudalis (TNC) [7–9]. Studies have suggested that microglia may participate in crosstalk with neurons through chemotaxis, phagocytosis, proinflammatory cytokine and neurotrophin production [10–12]. In a cortical spreading depression (CSD) model [13, 14], which mimics the aura of migraine, and the chronic inflammatory soup (IS)-triggered CM model, microglia are dramatically activated [15, 16]. In addition, our previous studies revealed that microglia and their purinergic receptors (P2 × 4R, P2 × 7R and P2Y12R) were significantly upregulated in the TNC after NTG injection, and inhibiting microglial activation, including morphological and inflammatory changes, might affect neuronal hyperexcitability in the TNC, which ultimately relieved CM-associated allodynia [17–19]. These findings demonstrate that TNC microglia play a crucial role in the central sensitization of CM, and a better understanding of the function of TNC microglia will help us to further understand the pathogenesis of CM.

Recently, Wang Yongxiang and colleagues provided the first evidence that activation of microglial glucagon-like peptide-1 receptor (GLP-1R) in the spinal cord specifically suppresses neuropathic pain, cancer pain, and diabetic hypersensitivity [20]. However, whether GLP-1R is involved in the central sensitization of CM has not yet been studied. GLP-1 is an endogenous insulinotropic hormone secreted from L cells of the small intestine, that participates in the homeostatic regulation of insulin and glucose by activating GLP-1R [21, 22]. GLP-1R is a kind of G-protein-coupled receptor. Activation of GLP-1R can inhibit apoptosis and inflammation by stimulating phosphoinositide 3-kinase (PI3K) and protein kinase A (PKA) [23]. GLP-1R expressed in the central nervous system (CNS) [24] may also be involved in regulating cell proliferation, neuronal excitability and synaptic plasticity [25–27]. However, the distribution and function of GLP-1R in the TNC have not yet been examined. Previous studies have revealed that migraine patients suffer from impaired insulin sensitivity and have higher blood glucose levels [28]. In addition, insulin-like growth factor-1 (IGF-1) treatment can inhibit CSD and calcitonin-gene-related peptide (CGRP) production, thereby relieving migraine-related hyperalgesia [29]. These data combined with the effect of GLP-1R in chronic pain suggest that activation of GLP-1R may also alleviate CM.

Based on these results, we hypothesized that GLP-1R in the TNC mediates microglial activation via the PI3K/Akt pathway and suppresses the central sensitization of CM. In the present study, we investigated whether activation of GLP-1R prevented allodynia and inhibited microglial morphological changes and inflammation in the TNC using a chronic nitroglycerin (NTG) injection-stimulated mouse model and the selective GLP-1R agonist liraglutide. We also confirmed the role of GLP-1R on microglia in lipopolysaccharide (LPS)-incubated BV-2 cells. In addition, we examined the involvement of the PI3K/Akt pathway in CM. Our findings suggest for the first time that TNC microglial GLP-1R activation suppresses the central sensitization of CM and that GLP-1R may serve as a new target for treating CM.

Materials and methods

Animals

Male C57BL/6 mice weighing 18–20 g were kindly provided by the Experimental Animal Center of Chongqing Medical University (Chongqing, China). Animal experiments were conducted in accordance with Chongqing Medical University Animal Ethics Committee and were approved by the National Institutes of Health guidelines on animal care. Mice were housed with a 12 h light/dark cycle, at a stable temperature of 23 ± 2 °C and humidity of 50 ± 10 %, and were given food and water ad libitum. Every effort was made to minimize the number of mice used in the experiments and their suffering.
Drug treatments
Nitroglycerin (NTG) (5.0 mg/ml, Henan Reagent, China) was freshly diluted to a final concentration of 1 mg/ml with saline, containing 6% propylene glycol and 6% alcohol. The intraperitoneal (i.p.) delivery of the diluted NTG was performed as described previously, that is, injected at a dose of 10 mg/kg every other day for 9 d (i.e., days 1, 3, 5, 7, and 9). Mice in the sham group were injected with an equivalent volume of saline, 6% propylene glycol, and 6% alcohol.

To measure the effect of GLP-1R in CM, a selective GLP-1R agonist (liraglutide) and an antagonist (exendin(9–39)) were applied in the experiment. Liraglutide (800 µg/kg; Selleck, TX, USA) and exendin(9–39) (50 µg/kg; MedChemExpress/MCE, USA), diluted with sterile saline, were administered i.p. for 16 consecutive days; that is, these drugs were administered 1 week before NTG injection. The time point for injections was also selected before NTG administration. To examine the role of PI3K/Akt in CM, the PI3K/Akt antagonist LY294002 (20 mg/kg; Selleck, TX, USA), diluted with sterile saline, was administered i.p. for 5 consecutive days; that is, these drugs were administered 1 week before NTG injection. The dose and delivery method of these drugs were based on previous research [30–33] and our experience.

Body weight and Blood glucose test
After a week of adaptation, the animals were randomly assigned to different experimental groups, as shown in Table 1 in which the experimental sets and sample size were delineated. During the whole experiment, the body weight and blood glucose of mice were measured 3 times, respectively, before drug administration, 1 week and 16 d after delivering liraglutide or exendin(9–39). The time point was selected at 9:00 prior to NTG injection. Glucose measurement was performed by a blood glucose meter (Sinocare, Changsha, China) using blood collected from the tail vein of mice.

Table 1: Schematic representation of experimental groups, sample size (number, n) and the sampling time (hour, h) of mice per group for different experimental analysis

| Experimental groups | Total (n) | Behavioural test (n) | WB (other) (n) | WB (c-fos) (n) | IF (other) (n) | IF (c-fos) (n) | Sampling time (h) |
|---------------------|----------|----------------------|----------------|----------------|---------------|----------------|------------------|
| Sham                | 9        | -                    | 6              | -              | 3             | -              | 24h after the first, the second, the third and the last NTG i.p. injections |
| NTG (1d)            | 6        | -                    | 6              | -              | -             | -              |                  |
| NTG (3d)            | 6        | -                    | 6              | -              | -             | -              |                  |
| NTG (5d)            | 6        | -                    | 6              | -              | -             | -              |                  |
| NTG (9d)            | 9        | -                    | 6              | -              | 3             | -              |                  |
| Sham                | 20       | 8                    | 6              | 6              | 4             | 4              | For c-fos: 2h after the last NTG/saline i.p. injection; For other targets: 24h after the last NTG/saline i.p. injection |
| Exe(9-39)           | 12       | 8                    | 6              | 6              | -             | -              |                  |
| Lira                | 12       | 8                    | 6              | 6              | -             | -              |                  |
| CM                  | 20       | 8                    | 6              | 6              | 4             | 4              |                  |
| CM+Exe(9-39)        | 20       | 8                    | 6              | 6              | 4             | 4              |                  |
| CM+Lira             | 20       | 8                    | 6              | 6              | 4             | 4              |                  |
| CM+LY294002         | 8        | 8                    | -              | -              | -             | -              |                  |

WB (other), western blot for GLP-1, GLP-1R, CGRP, Iba-1, IL-1β, TNF-α, PI3K and p-AKT; IF (other): immunofluorescence for GLP-1R, CGRP, GFAP, NeuN and Iba-1; Exe(9-39), exendin(9-39); Lira, liraglutide

BV-2 cell culture and treatment
BV-2 cells were provided by Procell Life Science & Technology (Wuhan, China). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, NY, USA) supplemented with 10% foetal bovine serum (FBS) (Gibco, NY, USA) and were maintained in a humidified incubator at 37 °C and 5% CO₂.

Cells were incubated with serum-free media for 24 h prior to each experiment and seeded at 1 x 10⁶ cells/dish in 100 mm culture dishes for western blotting and 3 x 10⁴ cells/well in 24-well culture plates for immunofluorescence. To study the role of GLP-1R in microglial inflammation, BV-2 cells were preincubated with the selective GLP-1R agonist liraglutide (100 nM, Selleck, TX, USA) and the antagonist exendin(9–39) (200 nM, MCE, USA) for 24 h, followed by LPS (1 µg/ml, Sigma–Aldrich, MO, USA) stimulation for 24 h. The doses of these drugs used with cells were based on previous data [34–36].

Behavioural tests
Mice were acclimated to the testing chambers for 3 successive days before the behavioural tests. All experiments were performed in a low-light room between 9:00 and 15:00 at time points before and 2 h after NTG injection.
The experimenter was blinded to the dug condition and the behavioural data analysis.

Both head-specific (periorbital) and hindpaw hyperalgesia were measured to reveal the hypersensitivity of the CM animal model. Mechanical responses were detected by a set of von Frey filaments (bending force ranging from 0.008 to 2 g, Aesthesio, USA) according to the up and down method [37, 38]. The first filament was chosen as 0.4 g. For periorbital testing, mice were placed in a paper cup to which they had previously been habituated, and then the periorbital region, positioned caudal to the eyes and near the midline, was stimulated with a von Frey filament. A positive response was considered quick retraction of the head or scratching of the face with the ipsilateral forepaw. In the absence of a response, a heavier filament (up) was applied, and in the presence of a response, a lighter filament (down) was applied. The duration of each stimulus was 3 s with an interval of at least 1 min. This process was followed for a maximum of 4 filaments after the first response. For hindpaw sensitivity, mice were habituated to acrylic cages 30 min before the test, and then the central area of the plantar surface of the hindpaw was stimulated with von Frey filaments. Positive responses were defined as lifting, shaking or licking of the paw. Testing was performed according to the up-down method described above.

Western blotting

To analyze the protein expression of GLP-1, GLP-1R, PI3K and p-Akt on different days after NTG intermittent injection, TNC samples were collected 24 h after the first (NTG 1d), the second (NTG 3d), the third (NTG 5d) and the last (NTG 9d) NTG injections. To examine c-fos expression, TNC tissues were collected 2 h after the last NTG injection, while for other protein targets, TNC was isolated and collected 24 h after the last NTG administration. The sampling time was shown in Table 1. Tissues were homogenized in cold RIPA lysis buffer (Beyotime, Shanghai, China) containing phenylmethylsulfonyl fluoride (PMSF, Beyotime, Shanghai, China) at 4 °C for 1 h. The total amount of protein was determined using a BCA protein assay kit. The following procedures were performed according to the method described above. Each analysis was repeated in three independent experiments.

Immunofluorescence staining and counting

To stained c-fos, TNC tissues were collected 2 h after the last NTG injection, while for staining other targets, TNC was collected 24 h after the last NTG administration. Mice were deeply anaesthetized and perfused transcardially with 30 ml of PBS (pH 7.4) followed by 30 ml of cold 4 % paraformaldehyde (PFA) in PBS. The whole brain and cervical spinal cord (C1-C2) were collected and postfixed with 4 % PFA overnight at 4 °C. The medullary segment including the TNC between +1 and −3 mm from the obex was removed and transferred to 30 % sucrose for 48 h. After being frozen at −80 °C, samples were cut into 10-µm-thick sections on a cryostat (Thermo). Sample sections were blocked in 5 % goat serum with 0.3 % Triton X-100 for 1 h at RT and then incubated overnight at 4 °C with the following primary antibodies: mouse anti-GLP-1R (1:50, Santa Cruz, CA, USA), mouse anti-GLP-1 (1:50, Santa Cruz, CA, USA), rabbit anti-GLP-1 (1:100, Santa Cruz, CA, USA), mouse anti-c-fos (1:200, Santa Cruz, CA, USA), rabbit anti-Iba-1 (1:1000, Abcam, Cambridge, MA, USA), rabbit anti-PI3K (1:1000, Proteintech, China), rabbit anti-Akt (1:1000, Proteintech, China), rabbit anti-phospho-Akt (1:2000, Cell Signalling, Boston, MA, USA), rabbit anti-IL-1β (1:800, Wanleibio, China), rabbit anti-TNF-α (1:800, Wanleibio, China), and mouse anti-β-actin (1:1000, Beyotime, China). After the membranes had been washed with TBST, the secondary antibodies (goat anti-rabbit, 1:1000; goat antimouse, 1:1000; Beyotime, China) were applied and incubated for 1 h at RT. After the secondary antibody reaction, the bands were visualized with enhanced chemiluminescence, and the positive pixel area was detected by an image analysis system (Fusion, Germany). The band sensitivities were normalized against the corresponding β-actin loading controls. The western blotting test was repeated six times for each target, and consistent results were obtained.

To investigate the expression level of various proteins in BV-2 cells, we collected cells after LPS incubation. Cells were lysed in cold RIPA buffer containing PMSF for 30 min at 4 °C, and the total protein concentration was determined using a BCA protein assay kit. The following procedures were performed according to the method described above. Each analysis was repeated in three independent experiments.
photographed with a confocal microscope (TCS Sp8, Leica). Quantification of the fluorescent signal intensity was performed by image analysis software (Image-Pro Plus 6.2, Media Cybernetics).

To quantify the immunoreactivity of CGRP and the numbers of c-fos- and iba-1-positive cells in the TNC, 6 sections per mouse from 4 mice were selected randomly for each group, and 6–8 visual fields per section were captured. Images centred on the superficial layer of the TNC were captured under a ×100 or ×200 objective, and the immunoreactive cells in this region were counted with Image-Pro Plus.

To quantify the number of GLP-1R-positive cells in the NTG (9d) group, we performed immunofluorescence and observed that the number of GLP-1R-positive cells in the TNC after NTG injection did not show a significant difference compared with that in the sham group (Fig. 1c). These results indicate that GLP-1R is dramatically upregulated in the TNC in NTG-induced CM model.

**Localization of GLP-1R in the TNC**

To localize the specific cell type for GLP-1R in the TNC, immunofluorescence was stained with Iba1-1 (microglial marker), GFAP (astrocytic marker) and NeuN (neuronal marker) using TNC sections in the CM group (Fig. 2a). Our images showed that GLP-1R-positive cells were mainly double labelled with Iba1 and GFAP but did not colocalize with NeuN (Fig. 2b). These results suggest that GLP-1Rs exclusively localize to glial cells but not to neuronal cells.

**Activation of GLP-1R attenuated CM-associated mechanical allodynia**

Considering the significant upregulation of GLP-1R in the TNC and the widely recognized effect of microglia in CM, it is reasonable to expect that GLP-1R may play an important role in the pathogenesis of CM. To study whether GLP-1R activation in TNC microglia can alleviate NTG-induced allodynia, the selective GLP-1R agonist liraglutide (800 µg/kg, \( n = 8 \) per group) and the antagonist exendin(9–39) (50 µg/kg, \( n = 8 \) per group) were i.p. injected for 16 d (Fig. 3a). The injection of the drugs started 1 week before NTG administration.

Liraglutide is a commonly used hypoglycaemic agent and is known to improve glucose homeostasis in diabetic patients [39]. To avoid the influence of hypoglycaemia on the experiment, we evaluated the changes in blood glucose and body weight of the experimental mice (Fig. 3b–c). The results showed that there was no significant difference in the levels of blood glucose in the various groups (Fig. 3b). Interestingly, the body weight of the CM group combined with liraglutide was significantly reduced compared with that of the sham group (Fig. 3c).

The periorbital and paw withdrawal thresholds were measured every other day from 1 to 9 d after NTG injection. The basal responses were evaluated before NTG, and the post-treatment responses were evaluated 2 h after NTG administration (Fig. 3d–g). We found that liraglutide (CM + Lira) markedly alleviated basal periorbital and paw hypersensitivity (\( p < 0.05 \)). Chronic exendin(9–39) (CM + Exe(9–39)) injection did not improve CM-associated allodynia. Only liraglutide and exendin(9–39) injection did not provoke a significant effect on mechanical hypersensitivity.

**Activation of GLP-1R suppressed NTG-induced CGRP expression in the TNC**

CGRP is a widely recognized migraine-related mediator and is also involved in central sensitization in the TNC. To further confirm the effect of GLP-1R on central
Fig. 1 Recurrent NTG injection increased GLP-1R expression in the TNC. a The white dotted line frame exhibits the TNC regions. b-d Representative western blot showing changes in GLP-1R and GLP-1 protein expression in the TNC on different days after NTG injection (b). The band intensities are presented as the percent (%) change relative to β-actin (c-d). Data are presented as mean ± SEM; n = 6/group; *p < 0.05, **p < 0.01 vs. sham group. e Representative immunofluorescence images of GLP-1R in the TNC in the sham and NTG (9d) groups. Arrowheads indicate GLP-1R. n = 3/group, scale bar: 20 μm
sensitization of CM, we measured alterations in CGRP expression in different drug-treated groups. The western blotting results showed that the protein level of CGRP in the TNC was significantly increased in the CM ($p < 0.001$) and GLP-1R antagonist exendin(9–39) treated groups ($p < 0.05$, Exe(9–39) vs. sham; $p < 0.001$, CM + Exe(9–39) vs. sham) (Fig. 4a-b). Activation of GLP-1R by its agonist liraglutide (CM + Lira) markedly suppressed the expression of CGRP compared with the corresponding level in the CM group (Fig. 4b, 0.58 ± 0.26 vs. 1.08 ± 0.12, $p < 0.01$). In addition, we performed immunofluorescence assessment of CGRP in the TNC (Fig. 4d). The density of CGRP-immunoreactive fibres in the TNC was increased in the CM and exendin(9–39) treated (CM + Exe(9–39)) groups compared with the sham group (Fig. 4c, $p < 0.001$). Consistent with the changes in CGRP levels in immunoblot analyses, the immunoreactivity of CGRP in the TNC in the CM group was significantly decreased by liraglutide treatment (Fig. 4c, $p < 0.001$).

**Activation of GLP-1R reduced NTG-induced c-fos expression in the TNC**

In addition to CGRP, we also detected alterations in c-fos expression in the TNC, which is a reliable marker of neuronal activation and is considered another mediator of central sensitization. Using western blotting, we found that the protein levels of c-fos in the TNC in the CM (1.13 ± 0.14) and exendin(9–39) treated group (1.08 ± 0.20) were significantly upregulated (Fig. 5a-b, $p < 0.001$ CM vs. Sham; $p < 0.01$ CM + Exe(9–39) vs. Sham), and liraglutide treatment markedly suppressed the expression of c-fos in CM mice (Fig. 5a-b, 0.72 ± 0.14, $p < 0.01$ CM + Lira vs. Sham). Consistent with the changes of c-fos levels in immunoblot analyses, the immunofluorescence results for c-fos in the TNC showed that the number of c-fos immunoreactive cells in the exendin(9–39) treated group (CM + Exe(9–39), 72.33 ± 14.95) was higher than that of sham group (39.83 ± 13.23) (Fig. 5c-d, $p < 0.01$); however, the number of c-fos positive cells in the liraglutide treated group (CM + Lira, 51 ± 11.22)
was significantly decreased compared with that in the CM group (72.67 ± 10.69) (Fig. 5c-d, p < 0.05).

GLP-1R contributes to microglial activation in the TNC in NTG-induced CM mice
We have indicated that chronic NTG stimulation induces an increase in the number and activity of microglia in the TNC. To study the involvement of GLP-1R in these changes, we measured microglia from TNC slices of different drug-treated groups using immunofluorescence. Quantification of Iba1-positive cells revealed that the number of microglia in the CM (272.6 ± 47.44) and exendin(9–39) treated group (CM + Exe (9–39), 269.2 ± 19.04) was significantly increased compared with that in the sham group (180.8 ± 26.41) (Fig. 6a,e, p < 0.01). The agonist liraglutide markedly suppressed the NTG-
induced upregulation of microglia in the TNC (Fig. 6a, e, CM + Lira 212.6 ± 26.92, *p < 0.05). We observed that the activated microglia in the TNC in CM mice manifested as hypertrophic somata and shortened processes; thus, we quantified the microglial processes in the highly magnified stacked images of Iba1-immunoreactive cells in the TNC (Fig. 6b–c). In addition, skeletal images of microglia in various groups were drawn for accurate quantification (Fig. 6d). The results showed that GLP-1R agonist liraglutide treatment partially reversed the NTG-induced shortening of both total (100.45 ± 40.55 μm vs. 67.99 ± 31.03 μm, **p < 0.01) and mean lengths (20.28 ± 8.11 μm vs. 14.63 ± 5.20 μm, ***p < 0.01) of microglial processes in the TNC (Fig. 6f–g).

In addition, we examined the protein level of Iba-1 in the TNC using western blotting and found that liraglutide markedly reduced NTG-induced upregulation of Iba-1 (CM + Lira 0.76 ± 0.12 vs. CM 1.01 ± 0.14, *p < 0.05) (Fig. 6h–i). We also detected the expression of the microglial proinflammatory factors IL-1β and TNF-α in the TNC during chronic NTG administration. The results showed that the protein levels of both IL-1β (*p < 0.01) and TNF-α (**p < 0.001) were increased after recurrent NTG and exendin(9–39) injection (Fig. 6h, j–k). However, the release of IL-1β and TNF-α in the TNC in CM mice was significantly reversed by chronic liraglutide treatment (Fig. 6h, j–k, **p < 0.01). Together, these results indicate that GLP-1R activity contributes to alterations in the number, morphology and inflammatory factor production of microglia in the TNC following NTG administration.

**Effect of GLP-1R on LPS-stimulated BV-2 microglial inflammatory cytokine release**

Because liraglutide and exendin(9–39) were administered systematically in vivo, to further determine the effect of GLP-1R on microglial function, we carried out experiments in BV-2 microglia. Using double-labelling immunofluorescence, we observed that GLP-1R was colocalized with Iba1 in BV-2 cells (Fig. 7a). After LPS stimulation, the expression of GLP-1R was significantly increased compared with that of the sham group (Fig. 7b–c, 0.89 ± 0.06 vs. 0.59 ± 0.06, ***p < 0.001). Exendin(9–39) incubation partially reversed the expression of GLP-1R induced by LPS. However, the agonist liraglutide induced higher upregulation of GLP-1R compared
with that in the LPS group. (Fig. 7b-c, 1.08 ± 0.19 vs. 0.89 ± 0.06, \( p < 0.05 \)). We also quantified the expression of Iba-1, IL-1\( \beta \) and TNF-\( \alpha \) after drug treatment, and the results showed that liraglutide reduced the protein level of Iba-1 (0.40 ± 0.11 vs. 0.68 ± 0.13, \( p < 0.01 \)) and reversed the production of IL-1\( \beta \) (0.38 ± 0.09 vs. 0.63 ± 0.13, \( p < 0.01 \)) and TNF-\( \alpha \) (0.52 ± 0.09 vs. 0.72 ± 0.10, \( p < 0.05 \)) induced by LPS (Fig. 7b, d-f). These results suggest that microglial GLP-1R mediates the inflammatory factor release of BV-2 microglia.

**GLP-1R is required for PI3K/Akt activation in the TNC following recurrent NTG injection**

Using western blotting, we measured the protein expression of PI3K and p-Akt in the TNC after repeated NTG injection (1, 3, 5, and 9 d post-injection) and found that these protein levels gradually increased in a time-dependent manner and peaked on day 9 (\( p < 0.05 \), PI3K in NTG 9d, 1.05 ± 0.18 vs. Sham 0.66 ± 0.17; \( p < 0.05 \), p-Akt in NTG 9d 0.69 ± 0.19 vs. Sham 0.40 ± 0.09) (Fig. 8a-c). Following recurrent treatment with the GLP-1R agonist liraglutide (CM + Lira), we observed a significant decrease in the expression of PI3K (0.68 ± 0.05 vs. 1.0 ± 0.18, \( p < 0.01 \)) and p-Akt (0.42 ± 0.07 vs. 0.79 ± 0.12, \( p < 0.001 \)) (Fig. 8d-f). The GLP-1R antagonist exendin(9–39) had no effect on NTG-induced PI3K and p-Akt expression levels. These results reveal that GLP-1R regulates PI3K/p-Akt activity in the TNC.
Fig. 6 (See legend on next page.)
Inhibition of PI3K/Akt activity alleviated NTG-induced mechanical hypersensitivity

To evaluate whether PI3K/ Akt is involved in NTG-induced pain hypersensitivity, we i.p. injected the PI3K antagonist LY294002 (20 mg/kg) 5 times prior to NTG injection every other day (n = 8 per group). The behavioural results showed that repeated LY294002 treatment partially reversed basal periorbital and paw hyperalgesia (Fig. 8g-j), which was markedly attenuated on days 7 and 9. However, LY294002 administration had no significant improvement in post-treatment allodynia induced by NTG. These data indicate that PI3K/Akt, downstream of GLP-1R, contributes to the development of CM.

Discussion

In the current study, we observed the following new findings. (1) Chronic NTG injection induced a dramatic increase in GLP-1R in TNC microglia. (2) Activation of GLP-1R attenuated CM-associated allodynia and reduced the expression of CGRP and c-fos. (3) Activation of GLP-1R suppressed microglial morphological changes and inflammatory factor release in the TNC in CM mice and in vitro. (4) The PI3K/Akt pathway, inhibited by GLP-1R in the TNC, was proven to participate in the development of CM.

Previous studies have found that GLP-1Rs are expressed in various tissues, including the pancreatic islets, brain, dorsal root ganglia, and spinal cord [20, 40–43]. Regarding the cellular localization of GLP-1R in the CNS, there are controversial findings. In the cerebral cortex, GLP-1R is expressed on neurons and glia [42], while in the spinal cord, GLP-1R is coexpressed only with microglia [20]. To date, there have been no studies on the distribution and localization of GLP-1R in the TNC. For the first time, we investigated that GLP-1R was widely expressed in the TNC and was specifically localized to microglia and astrocytes using immunofluorescence staining. Our western blotting data showed that GLP-1R protein expression in the TNC was increased after recurrent NTG injection. However, there is a major limitation that our present study includes only male animals. We have indicated that male mice could also successfully establish NTG induced CM model [17, 18], it is well known that sex differences in migraine is mainly due to the role of estrogen [44, 45], thus, to avoid the influence of estrogen, we selected male mice for further study. Whether the distribution and activation of TNC GLP-1R in female animals are different remains to be further studied.

We have indicated that the number of microglia in the TNC is also increased in this study and our previous studies [17, 18]. However, we did not find a significant upregulation of astrocytes in the TNC in this NTG-induced CM model in our previous researches. Considering the consistency of the alterations in GLP-1R and microglia in the TNC, we predict that the main reason for the upregulation of GLP-1R is due to the increased number of microglia. Consistent with our data, the upregulation of GLP-1R in the spinal cord on activated microglia was also found after peripheral nerve injury [20]. However, data on the changes in GLP-1R levels in other CNS disorders accompanied by microglial activation are contradictory. For example, the expression of GLP-1R in Alzheimer’s disease, experimental autoimmune encephalomyelitis and depression [46–48] was found to be decreased in the brain. The differences in GLP-1R expression in activated microglia might be due to the different regions of the CNS and the various methods for activating microglia. Together, our data reveal that activating TNC microglia may increase the expression of GLP-1R in CM mice in response to chronic NTG injection.

Our behavioural results showed that chronically activating GLP-1R by means of consecutive i.p. injections of the selective agonist liraglutide attenuated NTG-induced basal tactile allodynia. However, blocking GLP-1R did not improve CM-related hypersensitivity. This finding suggests that liraglutide mainly produces prophylactic analgesic effects. Liraglutide, a GLP-1 analogue, is a new therapeutic drug for the treatment of diabetes. The drug can cross the blood–brain barrier (BBB) and activate GLP-1R in the CNS [49, 50], thus producing neuroprotective and anti-inflammatory effects [50–55]. Previous data demonstrated that activation of GLP-1R could
alleviate neuropathic pain, cancer pain and diabetic neuropathy [20]. In the present study, we provide the first evidence that liraglutide prevented the development of CM by activating GLP-1R in the TNC. It is known that CM shares a common mechanism of central sensitization with chronic pain; thus, our data complement the impact of GLP-1R on chronic pain.

It is well known that GLP-1Rs themselves are inactive and needs to be activated or inhibited to exert their function. Therefore, to clarify whether the function of GLP-1R is activated or inhibited in CM, we detected the changes in the level of endogenous GLP-1, a natural agonist of GLP-1R, in the TNC in NTG-induced CM mice. We performed western blotting to examine the protein level of...
Fig. 8 Inhibition of PI3K/Akt pathway activity, which is regulated by GLP-1R, prevented NTG-induced allodynia. a-c Representative immunoblots of PI3K and p-Akt (Ser473) in the TNC on different days following NTG injection. The band intensities of PI3K and p-Akt are presented relative to those of β-actin and total Akt, respectively. Quantitative analysis revealed a dramatic increase on day 9 after NTG administration. Data are presented as mean ± SEM; n = 6/group; *p < 0.05 vs. sham group.
d-f Representative western blots showing the changes in PI3K and p-Akt (Ser473) protein expression in the TNC after liraglutide and exendin(9–39) treatment. The results showed that activation of GLP-1R by liraglutide markedly suppressed the increase in PI3K and p-Akt in the TNC in CM mice. Data are presented as mean ± SEM; n = 6/group; ***p < 0.001 vs. the sham group; ##p < 0.01, ###p < 0.001 vs. the CM group. Repeated treatment with the PI3K selective inhibitor LY294002 partially attenuated CM-associated basal periorbital (g) and hindpaw (h) mechanical hyperalgesia. Post-treatment responses, including periorbital (h) and hindpaw (j) mechanical allodynia, were assessed 2 h following NTG injection; however, LY294002 had no significant effect on NTG-induced acute allodynia. Data are presented as mean ± SEM; n = 8/group; two-way ANOVA and Bonferroni post hoc analysis; *p < 0.05, ***p < 0.001 and ****p < 0.0001 The CM and CM + LY294002 groups vs. the sham group; #p < 0.05 and ##p < 0.01 vs. the CM group.
endogenous GLP-1 in the TNC during repeated NTG administration and also conducted double-staining of GLP-1 and iba-1 to further detect the distribution of GLP-1 in the TNC. The results showed that GLP-1 was co-localized with microglia in the TNC, recurrent NTG administration decreased the number of GLP-1-positive cells compared with that in the sham group (Fig. S1). These results suggested that GLP-1 expression was gradually decreased in CM, and also revealed that although the protein expression of GLP-1R was upregulated after NTG stimulation, the amount of GLP-1Rs that can be activated was decreased, so the activity of GLP-1R in the TNC in CM model was actually inhibited. This data supports our behavioural analysis that activating GLP-1R by its agonist liraglutide plays a major role in relieving CM-related hyperalgesia.

Tactile allodynia is a clinical characteristics of CM patients which manifests as abnormal skin pain of the head and limbs [56], as we measured above (periorbital and paw responses); this is the external manifestation of central sensitization in the pathogenesis of CM. To further confirm the effect of GLP-1R on the central sensitization of CM, we examined the expression of CGRP and c-fos in the TNC. CGRP is a specific neuropeptide in the trigeminal system that plays a critical role in peripheral and central sensitization [9, 57]. Studies have indicated that NTG administration can induce the upregulation of CGRP in the TNC, dura mater, and blood [57]. C-fos, an immediate early gene that is widely considered a marker of neuronal activity, is also involved in central sensitization [58]. Studies in different animal models of migraine (NTG, CSD and I5 stimulation) demonstrate a significant upregulation of c-fos in laminae I and II of the TNC [59]. Our findings showed that activating GLP-1R by i.p. injection of liraglutide dramatically suppressed the upregulation of CGRP and c-fos in the superficial lamina of the TNC induced by NTG. This result, combined with our behavioural data, confirms that activation of GLP-1R in the TNC may inhibit the central sensitization of CM.

Accumulating evidence has revealed that changes in microglial functions (for example, morphological changes, process movement, and inflammation) are required for the development of chronic pain [60–62]. Our previous studies have indicated that microglial activation in the TNC contributes to the central sensitization of CM [17, 18]. Thus, we further explored whether GLP-1R is involved in CM by mediating microglial activation, including morphological changes and inflammation. In this study, chronic NTG injection induced an increase in microglial cell numbers and a significant reduction in microglial process length and inflammatory factor (IL-1β and TNF-α) release. Following liraglutide treatment, the upregulation of microglial cell number and proinflammatory factors was markedly decreased, and microglia exhibited much longer process lengths in the TNC. However, since the drugs were administered systemically in a simulated clinical manner, we cannot rule out the effect of GLP-1R in the peripheral system. Thus, we carried out experiments in BV-2 microglia to more accurately determine the effect of GLP-1R on microglial function. Consistent with the results in the CM animal model, GLP-1R is completely colocalized with BV-2 microglia, and activation of GLP-1R by liraglutide reduced iba-1 protein expression and inflammatory factors. From these data, we conclude that GLP-1R is involved in regulating TNC microglial activation during NTG injection, and this function of GLP-1R might also be the mechanism for attenuating CM-related allodynia. Although our data in vivo and in vitro demonstrated that activating GLP-1R inhibited microglial activation, changes in microglia induced by liraglutide can be indirect as well as behavioral effects could be driven by other cells cause our treatments are delivered systemically. Because of the limit of this study, the potential role of GLP-1R in the TNC still needs to be further explored.

Studies have indicated that GLP-1R is involved in regulating cell proliferation and migration, neuronal activity, and inflammation through its downstream PI3K/Akt pathway [23, 42, 63]. Moreover, PI3K/Akt has been reported to be upregulated in migraine [64], but no study has provided a direct evidence of whether this pathway participates in the mechanism of CM. Our study confirmed that the PI3K/Akt pathway acts downstream of GLP-1R in the TNC in CM mice. In addition, we observed that the protein expression of PI3K and p-Akt in the TNC gradually increased in the CM model, and inhibiting the PI3K/Akt pathway by repeated administration of the selective antagonist LY294002 relieved NTG-induced basal tactile allodynia. These results provide the first evidence that inhibiting the PI3K/Akt pathway attenuates CM-associated allodynia; that is, the pathway participates in the central sensitization of CM. The involvement of GLP-1R in the pathogenesis of CM may also be realized by regulating the activity of this pathway.

**Conclusions**

Our study demonstrated that the expression of GLP-1R is increased in TNC microglia after NTG injection. Activation of GLP-1R with its selective agonist liraglutide alleviated CM-associated allodynia and reduced the expression of CGRP and c-fos in the TNC. We also found that liraglutide inhibited NTG-induced microglial morphological changes (process retraction) and proinflammatory factor (IL-1β and TNF-α) production in the TNC. These functions of GLP-1R in the CM model is mediated by its downstream PI3K/ Akt pathway (Fig. 9). These findings provide new insights into the pathogenesis of CM and suggest that microglial GLP-1R in the TNC may be a new target for the treatment of CM. The GLP-1R agonist liraglutide, which is a commonly used hypoglycaemic drug in the clinic, might represent a new therapeutic approach for treating CM.
Abbreviations
BBB: Blood-brain barrier; CGRP: Calcitonin gene-related peptide; CM: Chronic migraine; CNS: Central nervous system; CSD: Cortical spreading depression; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Foetal bovine serum; GLP-1R: Glucagon-like peptide-1 receptor; IGF-1: Insulin-like growth factor-1; IS: Inflammatory soup; LPS: Lipopolysaccharide; NTG: Nitroglycerin; PI3K: Phosphoinositide 3-kinase; PKA: Protein kinase A; PMSF: Phenylmethylsulfonyl fluoride; RT: Room temperature; TNC: Trigeminal nucleus caudalis

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10194-021-01302-x.

Fig. 9 Schematic of the potential mechanisms of GLP-1R in the TNC in the CM animal model. After repeated NTG administration, microglia in the TNC are activated, and GLP-1R expressed on microglia is dramatically up-regulated. Activation of GLP-1R inhibits the function of the downstream PI3K/Akt pathway, thereby inhibiting microglial cell proliferation, morphological changes (shortening of the processes), and inflammatory cytokine (IL-1β and TNF-α) production and ultimately alleviating the central sensitization of CM.

Acknowledgements
None.

Authors’ contributions
FJ designed the study, performed the majority of the experiments and statistical analyses, and drafted the manuscript. QZ and YW helped conduct the cell experiments. YT and ZC provided useful advice on the experiments and the revision of this manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by Natural Science Foundation of Chongqing (cstc2018jcyjAX03602).

Availability of data and materials
The datasets used and analyzed in the present study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All animal experiments performed in this study were approved by the Ethics Committee for Animal Experimentation of Chongqing Medical University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests in the manuscript.

Author details
1Department of Histology and Embryology, Chongqing Medical University, No.1 Yixueyuan Road, Yuzhong District, 400016 Chongqing, China.
2Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences, No.118 Xingguang Avenue, Liangjiang New Area, 401147 Chongqing, China. 3Chongqing Key Laboratory of Neurodegenerative Diseases, No.312 Zhongshan First Road, Yuzhong District, 400013 Chongqing, China.

Received: 31 May 2021 Accepted: 21 July 2021
Published online: 29 July 2021

References
1. May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455–464
2. Global regional (2018) and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1–235.

3. Jiang H, Deng Y, Zhang Y, Jin J, Kong X, Zhu Q, Wang K, Zhou J (2016) Field testing of the ICHD-3β, expert opinion criteria for chronic migraine. J Headache Pain 17(1):85.

4. Scher AI, Stewart WF, Ricci JA, Lipton RB (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 104(1–2):81–91.

5. Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416.

6. Becker WJ (2017) The Diagnosis and Management of Chronic Migraine in Primary Care. Headache 57(10):1471–1481.

7. Su M, Yu S (2018) Chronic migraine: A process of dysmodulation and sensitization. Mol Pain 14:744886918767697.

8. Aurora SK, Brink MF (2017) Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. Headache 57(1):109–125.

9. Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the Trigeminal System in Migraine. Headache 59(5):650–681.

10. Tsuda M, Inoue K, Salter MW (2005) Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci 28(2):101–107.

11. Calvo M, Zhu N, Tsantoulas C, Ma Z, Grist J, Loeb JA, Bennett DL (2010) Neuregulin-ERBB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci 30(1):43–54.

12. Farkas E, Szilvásy-Szabó A, Ruska Y, Sinkó R, Rasch MG, Egebjerg T, Pyke C, Gispert JD, Chowen JA, García-Cuartero B, Gispert JD, Alvarez E, Martínez MD, Roncero I, Czech P (2018) Local GLP-1 receptor expression and function on nociceptive sensory neurons in the rat trigeminal ganglion. J Neuroinflammation 15(1):50.

13. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409–1439.

14. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837.

15. Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today 21(5):802–818.

16. Hamilton A, Hölscher C (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20(13):1161–1166.

17. Hamilton A, Patterson S, Porter D, Gault VA, Hölscher C (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89(4):481–489.

18. Abbas T, Faivre E, Hölscher C (2009) Impact of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res 205(1):265–271.

19. Liu J, Pang ZP (2016) Glucagon-like peptide-1 drives energy metabolism on the synaptic highway. FEBS J 283(24):4413–4423.

20. Zhang DG, Amin FM, Guo S, Vestergaard MB, Hougaard A, Ashina M (2020) Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura. Headache 60(4):655–666.

21. Liao L, Kraig RP (2020) Insulin-like growth factor-1 inhibits spreading depression-induced trigeminal calcitonin gene related peptide, oxidative stress & neural activation in rat. Brain Res 1732:146673.

22. Mousta PE, Abdelkader NF, El Awda SA, El-Shabrawy OA, Zahi HF (2018) Lisftagol ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling. J Neurochem 146(2):173–185.

23. Deng H, Yang F, Ma X, Wang Y, Chen Q, Yuan L (2020) Long-Term Lisftagol Administration Induces Pancreas Neogenesis in Adult T2DM Mice. Cell Transplant 29:6358972973292.

24. Peters CT, Choi YH, Brubaker PL, Anderson GH (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 131(8):2164–2170.

25. Sun Z, Sun L, Tu L (2020) GABA Receptor-Mediated P2X3/Akt Signaling Pathway Alleviates Oxious Stress and Neuronal Cell Injury in a Rat Model of Alzheimer’s Disease. J Alzheimers Dis 76(4):1513–1526.

26. Jia X, Ji L, Qiu Y, Ren Q, Gao Q, Tian Y, Li J, Zhang B, Sun H, Liu S (2020) A GLP-1 Analog Lisftagol Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-1β Signaling in Diabetic Swine. Front Cardiovasc Med 7:132.

27. Zhang Y, Yuan X, Wu Y, Pei M, Yang M, Wu X, Pang Y, Yang J (2020) Lisftagol regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo. J Dent 94:103310.

28. Zeigler C, Kreutzer G, Abbas M, Kassem M, Constantinescu AA, Boiriamé-Helms J, Yzer T, Galf F, Kessler L (2016) β-cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control. J Cell Mol Med 20(2):231–242.

29. Padhan AA, Smith ML, McGuire B, Tarash I, Kessler L (2016) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

30. Ben Aissa M, Tipton AF, Bertels Z, Gandhi R, Moye LS, Novack M, Bennett BM, Wang Y, Litosch V, Lee GH, Gasins IN, Thatcher GR, Pradhan AA (2018) Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. Cephalalgia 38(11):1471–1484.

31. Tamborlane WV, Barrientos-Pérez M, Fainberg U, Firmer-Larsen H, Hafez M, Hale PM, Jalcudali MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shahedeh N, Turan S, Weghuber D, Barrett T (2019) Lisftagol in Children and Adolescents with Type 2 Diabetes. N Engl J Med 381(7):637–646.

32. Tomehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS (2008) Expression and localization of the glucagon-like peptide-1 receptor in the trigeminal nucleus caudalis in a mouse model of chronic migraine. J Neuroinflammation 16:1.

33. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

34. Farkas E, Sálysvá-Szabó A, Ruska Y, Sinkó R, Rasch MG, Egebjerg T, Pyke C, Gereben B, Knudsen LB, Fekete C (2021) Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. J Cereb Blood Flow Metab 41(1):1526–1543.

35. S89

36. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

37. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

38. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

39. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

40. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

41. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

42. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.

43. Pradhan AA, Smith ML, McGuire B, Tarash I, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274.
48. Liu Y, Wang L, Pan D, Li M, Li Y, Wang Y, Xu Y, Wang X, Yan J, Wu Q, Lu L, Yuan K, Yang M (2021) PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats. Transl Psychiatry 11(1):26

49. Hunter K, Hölscer C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33

50. McClean PL, Parthsarathy V, Faivre E, Hölscer C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 31(17):6587–6594

51. Hansen HH, Barkholt P, Fabricius K, Jelsing J, Tenwel D, Pyke C, Knudsen LB, Vrang N (2011) The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res 1634:158–170

52. Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI (2017) Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease. Inflammopharmacology 25(3):369–382

53. Hakon J, Ruscher K, Rommer B, Tomasevic G (2015) Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PLoS One 10(3):e0120074

54. Li PC, Liu LF, Jou MJ, Wang HK (2016) The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci 17(1):37

55. Barreto-Vianna ARC, Aguila MB, Mandarim-de-Lacerda CA (2017) Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. Metabo Brain Dis 32(5):1735–1745

56. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47(5):614–624

57. Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158(4):543–559

58. Hermanson O, Telkov M, Geijer T, Hallbeck M, Blomqvist A (1998). Preprodynorphin mRNA-expressing neurones in the rat parabrachial nucleus: subnuclear localization, hypothalamic projections and colocalization with noxious-evoked fos-like immunoreactivity. Eur J Neurosci 10(1):358–367

59. Jones MG, Lever I, Bingham S, Read S, McMahon SB, Parsons A (2001) Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 21(6):643–655

60. Chen G, Zhang YQ, Qadri YJ, Serhan CN, Ji RR (2018) Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. NeuroReport 1006:1292–1311

61. Echeverry S, Shi XQ, Yang M, Huang H, Wu Y, Lorenzo LE, Perez-Sanchez J, Bonif DP, De Koninck Y, Zhang J (2017) Spinal microglia are required for long-term maintenance of neuropathic pain. Pain 158(9):1792–1801

62. Gu N, Eyo UB, Murugan M, Peng J, Matta S, Dong H, Wu LJ (2016) Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain. Brain Behav Immun 55:82–92

63. Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X, Wang J, Deng Z, Zeng Q, Zhang L, Wang Y, Hu XQ, Qiu W, Peng L, Lu ZQ (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation 16(1):242

64. Liu YY, Lao YZ, Li W, Tian Q (2017) PI3K/AKT signaling pathway activation in a rat model of migraine. Mol Med Rep 16(4):4849–4854

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.